EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

ONC201 has exhibited durable tumor regressions in midline high grade glioma patients. G protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) is overexpressed in high grade gliomas, controls several oncogenic mechanisms, and its antagonism causes tumor cell apoptosis. Using bioinformatic and G...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Benjamin Free, R, Cuoco, Caroline, Prabhu, Varun, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Robert Lane, J, Sibley, David, Allen, Joshua
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Experimental Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847112/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.365
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы